npj Breast Cancer (Jul 2024)

Cook and Move for Your Life, an eHealth intervention for women with breast cancer

  • Heather Greenlee,
  • Eileen Rillamas-Sun,
  • Rachel L. Yung,
  • Sofia Cobos,
  • Sidney M. Donzella,
  • Yuhan Huang,
  • Liza Schattenkerk,
  • Katherine Ueland,
  • Matthew VanDoren,
  • Samantha A. Myers,
  • Gino Garcia,
  • Theresa King,
  • Margarita Santiago-Torres,
  • Chongzhi Di,
  • Neelendu Dey,
  • Katherine A. Guthrie,
  • Nancy E. Davidson

DOI
https://doi.org/10.1038/s41523-024-00662-2
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 8

Abstract

Read online

Abstract We tested the feasibility and preliminary efficacy of an online diet and physical activity program for women with early-stage breast cancer who had completed surgery, chemotherapy, and radiation therapy (ongoing endocrine therapy allowed). Participants with low fruit and vegetable (F/V) consumption and/or low moderate-to-vigorous physical activity (MVPA) levels were randomized to one of two doses - low (one Zoom group session) or high (12 Zoom group sessions) - of an online lifestyle program with the goal of improving F/V intake and MVPA. All participants received eHealth communications (text messages, study website access), a Fitbit, and a WiFi-enabled scale. Primary objectives evaluated feasibility. Secondary objectives compared the 6-month change in F/V intake and MVPA between the two dose groups. Seventy-four women (mean age = 58.4 years; 87% non-Hispanic White; mean time since diagnosis = 4.6 years) were accrued. Among women in the low dose group, 94% attended the single session; among women in the high dose group, 84% attended at least 8 of the 12 sessions. Retention at 6 months was 93%. High relative to low dose participants consumed 1.5 more servings/day of F/V at 6 months (P = 0.007) but MVPA levels did not differ between groups. We successfully implemented an online lifestyle program for early-stage breast cancer survivors. The high dose intervention demonstrated preliminary efficacy in improving F/V consumption in early-stage breast cancer survivors. Future trials can test the intervention in a larger and more diverse population of breast cancer survivors.